 Hepatitis
C Top News Articles |
• | Taribavirin
Efficacy Similar to Ribavirin in Combination Therapy for Hepatitis C, but with
Less Anemia -
5/09/08 |
• | Natural
History of HCV-Related Cirrhosis after Liver Transplantation -
5/09/08 |
• | Pegylated
Interferon plus Ribavirin Is Effective for Patients with HCV-HBV Coinfection
-
5/09/08 |
• | Factors
Predicting Relapse in Patients with Genotype 2/3 HCV Treated with Pegylated Interferon
plus Ribavirin -
5/06/08 |
• | Nitazoxanide
Added to Standard Therapy Improves Response in Patients with Genotype 4 HCV: STEALTH
C-1 Study -
5/06/08 |
• | Cyclophilin
Inhibitor Debio 025 Exhibits Additive Activity against HCV in Combination with
Pegylated Interferon -
5/06/08 |
• | Boceprevir
Added to Pegylated Interferon/Ribavirin Increases Sustained Response in Treatment-naive
Patients and Some Prior Non-responders -
4/29/08 |
• | HCV
Polymerase Inhibitor R1626 Produces Good Response with Pegylated Interferon/Ribavirin
and Has High Barrier to Resistance -
4/29/08 |
• | R7128
Demonstrates Potent Anti-HCV Activity in Combination with Pegylated Interferon/Ribavirin;
Ongoing Trial to be Expanded -
4/29/08 |
• | Large
HCV RNA Decrease Reduces Adverse Clinical Outcomes, but Pegylated Interferon Maintenance
Adds Little Benefit (HALT-C) -
4/29/08 |
• | European
Association for the Study of the Liver (EASL) Meeting Opens in Milan -
4/24/08 |
• | Telaprevir
plus Pegylated Interferon and Ribavirin Allows Shorter Therapy for Patients with
Genotype 1 HCV -
4/24/08 |
• | Pegylated
Interferon Maintenance Demonstrates Benefits for Hepatitis C Patients with Portal
Hypertension -
4/24/08 |
• | Limitations
of an 8-week Course of Pegylated interferon plus Ribavirin for Genotype 2 Hepatitis
C Patients with Rapid Virological Response -
4/24/08 |
• | ViroPharma
and Wyeth Halt Development of HCV-796 for Hepatitis C -
4/24/08 |
• | Factors
Predicting Response to Therapy for Chronic Hepatitis C -
4/15/08 |
• | Liver
Gene Expression Predicts Response to Pegylated Interferon plus Ribavirin -
4/15/08 |
• | Combination
Therapy Improves Survival Time for Patients with Advanced Liver Cancer -
4/11/08 |
• | Deaths
Due to Hepatitis C Have Increased Dramatically over the Past Decade -
4/04/08 |
• | InterMune
Presents Top-line Results from Phase 1b Trial of HCV Protease Inhibitor ITMN-191
Monotherap -
4/04/08 |
• | Rates
of Hepatitis A and B Have Decreased Dramatically since 1990, but Drop in Hepatitis
C Has Leveled Off -
4/01/08 |
• | Valeant
Reports Promising 12-week Phase IIb Data on Taribavirin -
4/01/08 |
• | In
Vivo Experimental HCV Vaccine Shows Promise, but Dynavax/Merck HBV Vaccine Candidate
Put on Hold Due to Safety Concerns -
4/01/08 |
• | New
Network Will Send Drug Alerts Instantly to U.S. Doctors via Email -
4/01/08 |
• | FDA
Approves New Weight-Based Dosing Regimen for PegIntron plus Ribavirin -
3/28/08 |
• | Alcohol,
Tobacco, and Cannabis All May Promote Liver Disease Progression in People with
Chronic Hepatitis C -
3/28/08 |
• | Adiponectin
Level Predicts Liver Steatosis and Response to Interferon-based Treatment for
Chronic Hepatitis C -
3/21/08 |
• | Vertex
and Tibotec Start Phase 3 Study of Telaprevir for Treatment-Naive Genotype 1 Hepatitis
C Patients -
3/21/08 |
• | Use
of Different Pegylated Interferon/Ribavirin Regimens after Rapid Virological Response
Does Not Affect Sustained Response Rate -
3/18/08 |
• | Study
Confirms Hepatitis C Is a Risk Factor for Non-Hodgkin's Lymphoma -
3/18/08 |
• | Pathology
of Chronic Hepatitis C in Children: Peds-C Trial -
3/14/08 |
• | Non-invasive
Markers for Liver Fibrosis in Hepatitis C Patients with Normal ALT -
3/11/08 |
• | Pegylated
Interferon plus Ribavirin for Patients with HCV-related Liver Cirrhosis -
3/11/08 |
• | FDA
Grants Priority Review of Eltrombopag (Promacta) for Thrombocytopenia -
3/07/08 |
• | Benefits
of Screening for HCV Infection Based on Risk Factors -
3/07/08 |
• | Methamphetamine
Promotes Hepatitis C Virus Replication in Human Liver Cells -
3/07/08 |
• | FibroScan
for Diagnosis of Fibrosis in Patients with Acute Viral Hepatitis and Recurrent
Hepatitis C -
3/04/08 |
• | Insulin
Resistance is a Risk Factor for Liver Fibrosis Even without Steatosis
-
2/29/08 |
• | New
Upper Limit Defined for Normal ALT in Adolescent Males -
2/26/08 |
• | Genetic
Variations in HCV Genotype 3 Core Protein Promote Liver Fat Accumulation -
2/26/08 |
• | OctoPlus
Initiates Phase IIa Study of Locteron Controlled-release Interferon
-
2/22/08 |
• | Asians
with HCV Genotype 3 Do Not Respond as Well as Caucasians to Interferon-based Therapy
-
2/19/08 |
• | Naringenin
Compound in Grapefruit Inhibits HCV Replication in Laboratory Study -
2/19/08 |
• | SciClone
and Sigma-Tau Report Interim Results from Phase 3 Trial of Thymalfasin (Zadaxin)
for Non-responder Hepatitis C Patients -
2/15/08 |
• | Migenix
Adds Higher 600 mg Celgosivir Dose of Celgosivir in Phase II Study -
2/12/08 |
• | Silymarin
(Milk Thistle) Does Not Affect Hepatitis C Virus Activity or ALT Levels in HCV
Patients, but Users Report Fewer Symptoms and Better Quality of Life than Non
Users - 2/05/08 |
• | Non-Invasive
Ways to Assess Liver Disease: Studies Test Alternatives to Liver Biopsy - 2/05/08 |
• | Vertex
to Start Phase 3 Trials of HCV Protease Inhibitor Telaprevir (VX-950) - 2/01/08 |
• | Insulin
Resistance Linked to Lower Treatment Response in Genotype 2/3 Patients - 2/01/08 |
• | Liver
Steatosis Is Common in Hepatitis C Patients, Especially Those with Genotype 3
- 2/01/08 |
• | Duration
of Pegylated Interferon plus Ribavirin for HCV Genotypes 2 and 3 - 1/29/08 |
• | HCV
Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment - 1/29/08 |
• | Crack
Pipes Can Transmit Hepatitis C Virus - 1/29/08 |
• | Interferon-based
Therapy Lowers Lymphoma Risk in Hepatitis C Patients -
1/25/08 |
• | Frequent
Cannabis Use is Associated with Liver Fibrosis Progression in Hepatitis C Patients
- 1/25/08 |
• | Albuferon
Dose in Ongoing Trials is Lowered Due to Safety Concerns -
1/25/08 |
• | Hepatology
Expert Discusses PegIntron vs Pegasys IDEAL Study Findings - 1/18/08 |
• | Preliminary,
Top-line Results from Schering Plough's IDEAL Study: PegIntron versus Pegasys
- 1/14/08 |
• | Possible
New Method for Detecting and Monitoring Liver Disease without Liver Biopsies
- 1/14/08 |
• | Use
of CT Scans to Monitor Liver Fibrosis in People with Hepatitis C - 1/14/08 |
• | InterMune
Announces Progress on HCV Protease Inhibitor ITMN-191 -
1/11/08 |
• | Pharmasset
Announces Promising 4-Week Data on Combination Therapy with HCV Polymerase Inhibitor
R7128 - 1/11/08 |
• | Growth
Hormone Deficiency Common in Hepatitis C Patients, but Improves with Interferon-based
Treatment - 1/08/08 |
• | Pegylated
Interferon plus Ribavirin in the Treatment of Chronic Hepatitis C Genotype 4
- 1/08/08 |
• | Psychiatric
Illness and Substance Use in Veterans with and without Hepatitis C - 1/08/08 |
• | Duration
of Pegylated Interferon plus Ribavirin May Be Tailored Based on Early Response
- 1/04/08 |
• | Human
Genetic Variation May Protect Against HCV-related Liver Disease Progression
- 1/04/08 |
• | Eltrombopag
Raises Platelet Counts, Enabling Initiation of Interferon-based Therapy for Hepatitis
C - 12/14/07 |
• | HCV
Polymerase Inhibitor R7128 Demonstrates Antiviral Activity in Prior Non-responders
- 12/14/07
|
• | Experimental
HCV Polymerase Inhibitor GS 9190 Shows Promising Antiviral Activity but Possible
Cardiac Side Effects in Phase 1 Study -
12/11/07 |
• | Acute
Hepatitis C Infection and Spontaneous Viral Clearance in Adults and Children
- 12/11/07
|
• | Good
Response to Hepatitis C Treatment in Patients with a History of Psychiatric Conditions
- 12/11/07
|
• | Non-invasive
FibroTest and FibroScan Predict Liver Cirrhosis Better than Earlier Stages of
Fibrosis in Hepatitis C Patients -
12/11/07 |
• | Experimental
Polymerase Inhibitor HCV-796 is Safe and Effective in Combination with PegIntron
or Pegasys
- 12/07/07 |
• | Novel
HCV Polymerase Inhibitor VCH-759 Monotherapy Demonstrates Promising Antiviral
Activity -
12/07/07 |
• | Polymerase
Inhibitor NM107 and Protease Inhibitor Boceprevir Show Enhanced Anti-HCV Activity
in Combination -
12/07/07 |
• | Anti-HCV
and Anti-fibrotic Effects of Drugs Used for Other Indications
-
12/04/07 |
• | Experimental
Botanical Therapies for Hepatitis C-
12/04/07 |
• | Different
Treatment Outcomes among Individuals Infected with the Same Strain of HCV-
12/04/07 |
• | Liver
Stiffness Measurement (FibroScan) More Useful for Assessing Fibrosis in Patients
with HCV Compared with HBV-
12/04/07 |
• | New
Controlled-release Interferon Alfa (Locteron) Demonstrates Promising Activity
against HCV
- 11/30/07 |
• | Depression
Due to Treatment with Pegylated Interferon plus Ribavirin May Be Under-diagnosed
by Clinicians -
11/30/07 |
FDA-approved
Treatments
